Grifols S.A. American Depositary Shares (GRFS)
StalwartFairStock Score: 70/100 — STEADY
Key Financials
| Current Price | $7.66 |
| Market Cap | $5.5B |
| P/E Ratio | 10.79 |
| ROE | 6.13% |
| Dividend Yield | 2.3% |
| Sector | Healthcare |
Strengths
- Generates $1.0 billion in annual free cash flow (18.6% yield on market cap)
- Attractive 2.1% dividend yield providing steady income returns
- FairStock composite score of 70/100 places it in the top tier across value, quality, and momentum factors
- Established organization with 25,258 employees providing operational scale
Concerns
- Altman Z-Score of 0.6 places it in the financial distress zone—elevated bankruptcy risk
AI Analysis
Grifols S.A. American Depositary Shares is a small-cap healthcare company valued at $5.5 billion. The business generates $7.5 billion in annual revenue with a 1.3% net margin and $1.0 billion in free cash flow. From a quality standpoint, Grifols shows distressed Altman Z-Score of 0.6 warrants caution and modest 6% ROE. On valuation, the stock is attractively valued at 11.4x earnings, with a modest 26% margin of safety vs Graham Number. Growth dynamics show revenue growing at 0.3% and profit growth of 42.5%. The 2.1% dividend yield adds an income component for patient holders. Our composite FairStock Score of 70/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.
Bull Case
Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $1.0 billion in annual free cash flow (18.6% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.
Bear Case
Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer